CAS: 133099-07-7; (S)-2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)Ethyl)Pyrrolidin-3-yl)-2,2-Diphenylacetamide Hydrobromide

上下游产品

CAS号133033-99-5 氧化达非那新杂质 | CAS号127264-14-6 5-(2-溴乙基)-2,3-二氢苯并呋喃 | CAS号134002-25-8 3-(S)-(1-氨基甲酰-1... | CAS号133099-04-4 达非那新 | CAS号943034-50-2 5-(2-氯乙基)-2,3-二氢苯并呋喃 | CAS号87776-76-9 2,3-二氢-5-苯并呋喃乙醇 | CAS号1189753-52-3 (S)-2,2-dipheny... | CAS号133099-11-3 (S)-alpha,alpha... | CAS号90843-31-5 5-乙酰基-2,3-二氢苯并[b]呋喃 | CAS号151427-19-9 2-溴-1-(2,3-二氢-1... | CAS号133099-04-4 达非那新

达非那新置于氢溴酸体系中,用 水,丁酮 用作溶剂,化学反应生成氢溴酸达非那新
参考文献: A Method For The Preparation Of Darifenacin Hydrogen Bromide[fr] Procédé De Préparation De Darifénacine Bromhydrique
标题: A Method For The Preparation Of Darifenacin Hydrogen Bromide[fr] Procédé De Préparation De Darifénacine Bromhydrique
摘要:一种制备(3S)-L-[2-(2,3-二氢-5-苯并呋喃基)乙基]-α,α-二苯基-3-吡咯烷乙酰胺溴化氢的方法,其中3-(S)-[(I-氨基甲酰)-1,1-二苯甲基]吡咯烷或其与有机酸的盐在无机碱存在下与5-(2-溴乙基)-2,3-二氢苯并呋喃在水和c6到c9脂肪,脂环或芳香族烃类有机溶剂的异相体系中进行烷基化反应,分离两相后得到粗的达瑞那新碱基,再加入c3到c9的酮或c3到c9的醇和浓盐酸转化为溴化氢盐.

专利信息

专利号:WO-2009153649-A1
优先权日:2008-06-19
标 题:Process for preparing 3-substituted pyrrolidine compounds
发明人：SOLDEVILLA MADRID NURIA
权利人:MEDICHEM SA; SOLDEVILLA MADRID NURIA
摘要:Disclosed is a process for preparing 3 -substituted pyrrolidine compounds of formula (VII) or salts thereof, wherein R1 is described herein, which are intermediate compounds useful for the synthesis of darifenacin which is indicated for the treatment of overactive bladder with symptoms of urge, urinary incontinence, and the like, and pharmaceutically acceptable salts thereof. Also disclosed is a process for preparing darifenacin and pharmaceutically acceptable salts thereof.

专利号:US-2022370487-A1
优先权日:2021-05-10
标题 :Compositions targeting sodium channel 1.6
发明人：AMBROSI CHRISTINA; WILLIAMS LUIS; LEWARCH CAITLIN; GERBER DAVID; MCMANUS OWEN; AGRAWAL SUDHIR; DEMPSEY GRAHAM T
权利人:Q STATE BIOSCIENCES INC
摘要:The invention provides therapeutic compositions that include an antisense oligonucleotide (ASO) complementary to an identified target on a Nav channel mRNA. The ASO hybridizes to its target RNA and forms a duplex that recruits RNase H to degrade the RNA, thereby downregulating Nav channel synthesis, which inhibits the neuron's ability to contribute to certain conditions such as epilepsy and pain perception. The ASO binds to one of the specific identified targets, and may be provided as a gapmer that includes a central DNA segment flanked by modified RNA wings.